Heufelder Jens

Gollrad Johannes, Böker Alexander, Vitzthum Sebastian, Besserer Angela, Heufelder Jens, Gauger Ulrich et al.

Proton therapy effectively treats iris melanoma with low recurrence/metastasis. However, large treatment fields (over 10 clock hours) significantly increase secondary glaucoma and vision loss risk.

Riechardt Aline I, Stroux Andrea, Seibel Ira, Heufelder Jens, Zeitz Oliver, Böhmer Dirk et al.

This study found that for choroidal melanoma proton therapy, the radiation dose to the optic disc, not the irradiated optic nerve length, is the primary predictor for secondary glaucoma and other severe ocular complications.

Hager Annette, Meissner Friederike, Riechardt Aline-Isabel, Bonaventura Theresa, Löwen Julia, Heufelder Jens et al.

This study found choroidal melanoma eyes show increased inflammation after proton beam therapy, especially with larger tumors. This suggests LFP can monitor treatment response and guide planning.

Seibel Ira, Riechardt Aline I, Erb-Eigner Katharina, Böker Alexander, Cordini Dino, Heufelder Jens et al.

Proton beam therapy for uveal melanoma with posterior extraocular extension, including optic nerve invasion, showed no local recurrences over long-term follow-up. This suggests it's a safe and effective treatment option.

Seibel Ira, Riechardt Aline I, Heufelder Jens, Cordini Dino, Joussen Antonia M

This study found adjuvant endoresection or endodrainage after proton therapy for uveal melanoma reduces enucleation, radiation retinopathy, and neovascular glaucoma, improving globe preservation.

Riechardt Aline I, Cordini Dino, Rehak Matus, Hager Annette, Seibel Ira, Böker Alexander et al.

Trabeculectomy effectively lowered IOP in glaucoma patients after proton beam therapy for uveal melanoma, reducing medication. However, secondary interventions and metastasis risk require careful patient selection and tumor control.

Willerding Gregor D, Cordini Dino, Hackl Christoph, Karle Bettina, Lakotka Nona, Foerster Michael H et al.

Proton beam radiotherapy for diffuse iris melanoma achieved excellent tumor control (96.3%), preserving vision in most patients despite common side effects like cataract and glaucoma, offering a viable alternative to enucleation.